ObjectiveTo compare the incidence of hypotension between remimazolam and sevoflurane under general anesthesia for cardiac catheterization of congenital heart disease. DesignRetrospective observational study. SettingA single university hospital with 300 pediatric cardiac catheterizations by general anesthesia performed annually. ParticipantsPatients younger than 15 years who underwent cardiac catheterization under general anesthesia between March 1, 2021, and December 31, 2022. Exclusion criteria: general anesthesia maintained with other than remimazolam or sevoflurane, the administration of remifentanil, ASA score of 4–5, emergency procedures, and no direct arterial pressure measurement. InterventionsGeneral anesthesia was maintained with remimazolam or sevoflurane. Measurements and Main Results309 patients were analyzed, 28 in the remimazolam group and 281 in the sevoflurane group. Propensity score matching adjusted for confounding factors resulted in 28 patients in each arm, with no apparent differences in background factors. Hypotension was defined as a time-averaged area of systolic arterial pressure falling below 80% of the baseline from the start of anesthesia to the end of procedure that was > 1. Significance level: p < 0.05. The incidence of hypotension was 39.3% in the Remimazolam and 46.4% in the Sevoflurane with no significant difference (p=0.79), although the ratio of median systolic arterial pressure to the baseline was significantly higher in the Remimazolam: 91.4 (SD: 15.2)% vs 83.2 (SD: 11.4)% in the Sevoflurane (p=0.03). ConclusionsRemimazolam did not result in lower hypotension incidence than sevoflurane during pediatric cardiac catheterization for congenital heart disease, while maintaining significantly higher blood pressure overall.
Read full abstract